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This year for the nineteenth time the International Scientific and Professional 
Conference Accounting and Management will be held in Zadar from 13 to 14 
September 2018. It is organized by the Croatian Accountant, the association of 
accountants, tax advisors and financial experts and the RRiF College of Financial 
Management. 
The Conference has gathered university professors, business college lec-
turers and polytechnics lecturers as well as the professionals from the world of 
business. Every year it is created by the Conference Organization Committee, 
authors, co-authors, reviewers and conference lecturers. 
The goal of the Conference is to publish and present scientific and profes-
sional papers, to exchange experience and to contribute to the development 
of accountancy and management in the EU countries and the countries in the 
region.
We are extremely proud that this year the largest number of authors and co-
authors have expressed their interest in publishing and presenting papers. The 
papers comprise analyses and research of the topics in the field of accounting, 
taxes and management, which contributes to the development of the econo-
mist profession and the entire economy.
We thank all the authors, co-authors and reviewers for their effort and will-
ingness to share their knowledge and to enable the organization of the Confer-
ence as well as publishing of these Proceedings.
For the Editorial Board:
Đurđica Jurić, PhD, College Professor
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INNOVATION AND SUSTAINABILITY: DISCLOSURE 
PRACTICES OF HUNGARIAN PHARMACEUTICAL 
COMPANIES
ABSTRACT
Today, innovation and sustainability are issues that organizations need to address 
when they compose their strategies. Moreover, it is not enough to align these with 
organizational objectives, it is also necessary to inform the stakeholders about the 
firms’ attitude towards R&D&I and its connection with sustainability. The tool for this 
communication – besides the narrative parts of traditional financial statements – is 
voluntary reporting. This paper presents an empirical research about the disclosure 
practices of dominant actors of the Hungarian pharmaceutical industry: the aim of 
the content analysis is to discover items related to innovation and sustainability in the 
mandatory and voluntary reports issued by companies. This is done in order to sup-
port planned future research aiming to compare the disclosure practices of different 
reporting environments. We concentrate on the Hungarian market at this initial phase 
because our first aim is to come up with a list of items to search for in financial state-
ments. Results show that the reporting practices of the sample firms are determined 
by the requirements of the Hungarian Accounting Act. Voluntary reporting and volun-
tary disclosure were found only in case of the sole public entity in the sample, which 
presented the highest scores. Another important finding is that the two areas of our 
interest were not interlinked in the statements, so companies did not report on the 
sustainability aspects of their research practices.
Key words: innovation, sustainability, disclosure practices, voluntary re-
porting
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1. INTRODUCTION
Pharmaceutical companies face multiple challenges regarding profitabili-
ty and sustainability due to their special role. These companies are expected to 
produce medicines for the sake of the human kind in a way that does not harm 
the needs of future generations. On the other hand, achieving profitability and 
satisfying several groups of stakeholders – investors, creditors, states, authori-
ties, the public etc. – are goals that must be met by the organizations. The 
sector has a two-tier structure: few large multinational research-based firms 
comprise the market with a larger number of smaller companies who do not 
have a significant role in bringing great innovations to the customers (Blum-
Kusterer–Hussain 2001).
Large pharmaceutical entities operate in a highly intense competitive en-
vironment on the medicine market, where research and innovation is a must 
due to the above mentioned complex set of short-term and long-term objec-
tives. Of course, protecting intellectual property rights with patents in this sit-
uation is very important in order to maintain and control the results of intense 
R&D expenditure. 
 From an ethical aspect, pharmaceutical companies should act fair towards 
society and improve their corporate social responsibility (CSR) involvement 
(Lee–Kohler 2010). CSR in general can be defined as a ‘set of procedures and ac-
tions adopted by organizations to promote good practices in the management of 
economic, social and environmental aspects’ (AECA 2004; Gelbmann 2010 cited 
by Haro-de-Rosario et al 2016 p 176). 
Thus there is a moral obligation for firms to report on such delicate is-
sues which are not treated routinely in traditional accounting: environmental 
issues, human resource, innovation capacity and strategies. These topics have 
one very important feature in common: they would be classified in accounting 
as intangible assets or commitments, but usually they are not listed on the Bal-
ance Sheets due to strict recognition criteria in accounting regulations. So the 
task is to find out how to incorporate such important strategic questions into 
company-level communication which are traditionally not reported as part of 
annual statements.  
As we can see in the literature there are plenty of examples for research 
related to “sustainability,” “corporate and social responsibility” (CSR), “corporate 
responsibility” (CR), and “triple bottom line” (TBL) (Idowu et al 2016 p 1.). The 
terms are sometimes used as if they were synonyms. Undoubtedly, new ways 
of reporting are emerging, and in the future integrated reporting is going to 
be in the centre of attention (Dumitru-Jinga 2015). 
Moreover, the idea of sustainability may appear in other areas than CSR 
reporting. The idea of responsible research and innovation (RRI) is that social, 
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ethical and environmental aspects should be taken into consideration during 
the implementation of research, development and innovation projects (Luko-
vics et al 2017). This also brings the issue of sustainability reporting to a new 
level, challenging the policy makers to set standards that lead to comparable 
reports providing the stakeholders information about the entities’ attitudes to-
ward such responsibilities. 
As for the European pharmaceutical industry, the research and develop-
ment expenditure in 2016 was 33,949 million € and 178 million € in Hungary 
(EFPIA 2018 p 7). The production of the Hungarian market for the same year 
was 3,050 million € (EFPIA 2018 p 12). The sector has been growing in the re-
cent years: investments for increased 13 percent in 2017 mainly due to the 
most significant firms of the market (KSH 2017 p 7). The majority of perfor-
mance of the Hungarian pharma sector is deriving from four massive actors 
each of which carries out research and development activities: Richter Gedeon 
Nyrt., Egis Nyrt., Teva and Sanofi Group. The volume R&D spending of these 
firms is outstanding even in a European perspective and includes all levels of 
research and product development (Sipos–Cseh 2014 p 143). This makes the 
Hungarian pharma sector a logical choice for exploring the financial and vol-
untary reporting practices for R&D aspects.
Our research aim is to find out how research-intensive participants of the 
Hungarian pharmaceutical industry communicate about their R&D&I efforts 
and sustainability issues. We concentrate on the Hungarian market at this ini-
tial phase of the research because our first aim is to come up with a list of items 
to search for in the financial statements. Firstly, it is necessary to frame an in-
dex that can be applied later during the course of future research extended to 
several European countries. Similarly to Bellora–Guenther (2013) we analysed 
the statements manually because we intended to rely on our understanding of 
the published data instead of computer software. The most logical way to do 
this is to read financial statements published in our country to avoid language 
barriers. Our final aim is to be able to compare the reporting culture of the 
Hungarian pharmaceutical sector with more developed countries in Europe.
We apply the methodology of annual statement content analysis. We de-
sign a list of the most important items based on previous literature (Ragini 
2012) and search for the items in the mandatory and voluntary annual reports 
of the sample entities in order to get information about the level of disclosure. 
The structure of this paper is as follows: after the introduction, the second part 
deals with sustainability reporting practices in the pharmaceutical sector. The 
third section presents the research methodology along with the sample and 
the main results. The last section contains the conclusions.
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2. SUSTAINABILITY REPORTING PRACTICES
As accounting is a tool of communication with the stakeholders, it has a 
key role in providing necessary information to the proper groups of interested 
parties. In terms of reporting channels, there is financial accounting which re-
sults in systematic and standardized statements prepared for external stake-
holders by firms based on local accounting standards. The content of these 
documents in not restricted to the mandatory elements, but evidence shows 
that in Hungary the intangible reporting culture of the largest companies is 
basically determined by the requirements of the regulations which state what 
kind of information has to be included in the narrative parts of the statements. 
Listed companies – which enclose the business report to the financial state-
ments – are exceptions: in their case voluntarily disclosed information is also 
significant (Kovács 2015). 
However, in the near past, there have been voices saying that support-
ing short-term decision making is not the only objective of financial report-
ing. Stakeholders also need information about whether the entity has been 
managed in a way that reflects their interests, which leads us to the issue of 
stewardship or accountability. The reasoning includes that even if a primary 
user is not currently considering a buy or sell decision, they could be interested 
is understanding the entity’s strategy and value creation in the longer term 
(EFRAG et al 2013).
The European Union has recently put more emphasis on the issue of re-
porting information related to the firms’ social and environmental responsibil-
ity. Directive 2013/34/EU already required entities to include issues related to 
environmental and social aspects in the management report. Later, directive 
2014/95/EU amended the former regulation to enhance the disclosure of non-
financial and diversity information by certain large undertakings and groups, 
leading all member states to incorporate these rules in their accounting regu-
lations (in Hungary this lead to an amendment in the Hungarian Act on Ac-
counting). The directive also mentions the aim of the development of such 
frameworks that serve as common basis for sustainability reporting, setting 
already existing ones as examples. 
Besides mandatory reporting, another tool is voluntary disclosure, which 
is a much more flexible and non-standardized method of communication usu-
ally focusing on non-financial information. Sustainability issues have been 
dealt with for decades in dedicated statements focusing on the so called triple 
bottom line (i.e. social, environmental and economic) aspects. From the 1980’s, 
annual statements began to incorporate the management commentary, en-
vironmental reporting and governance or remuneration reports as new tools 
to address multiple information needs of a broader audience (Dimitru–Jinga 
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2015). In the new millennium, sustainability reporting emerged and according 
to Blum-Kusterer–Hussain (2001) the pharmaceutical sector’s contribution to 
the topic was linked to such issues as global warning, ozone depletion, reduc-
tion of emissions, the efficient use of resources, the disposal of unused prod-
ucts and packaging, biodiversity, animal ethics, genetic engineering and the 
impact of consumption. The authors study the process of eco-change in the 
pharmaceutical industry and define eco-innovation as ‘changes to the produc-
tion process that decrease the product’s impact on the natural environment 
and/or increase intra-generational or inter-generational equity’ (Blum-Kuster-
er–Hussain 2001, p 301).  
As a consequence of the need for this kind of communication, new or-
ganizations emerged establishing frameworks for voluntary integrated report-
ing (e.g. International Integrated Reporting Council – IIRC). The advantages of 
creating such standards is that the users of companies’ statements get infor-
mation on the organizations’ long-term non-financial goals and value creation 
which is standardized on some level. This also helps businesses to build trust 
with a wide range of stakeholders and create a favourable image. According to 
Rosario-de-Haro (2016), CSR disclosure has to be treated in the pharmaceutical 
sector as a strategic issue and the method of disseminating the information 
to stakeholders is also an important question to be considered. The authors 
analysed the information published by firms in the Spanish pharmaceutical 
industry provided in sustainability reports and CSR reports available online. 
The researchers found 50 such reports online from a preliminary sample of 
315 companies chosen by sector and firm size, meaning that around 16% of 
the entities published them (Rosario-de-Haro 2016, p 180.). The authors also 
state that in order to get to the public, a new kind of approach is necessary and 
annual statements need to cover the leading topics of communication (e.g. 
corporate strategy, operational and financial reports along with CSR issues) in 
integrated reports. 
As today, information technology is an area of constant development, 
internet plays a key role in the technical implementation of communication 
with the users of annual statements. In this way, transparency and interaction 
with the stakeholders can be brought to another level in the future, meaning 
that the once-in-a-year reporting will probably be replaced with day-to-day 
communication and interaction. There is also a rationale for the companies to 
invest in internet financial reporting, since according to research, it can be a 
factor that affects financial performance for specific firms (see Pinto–Ng Picoto 
2016).
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3. RESEARCH METHODOLOGY AND RESULTS
Our chosen methodology is content analysis of financial statements and 
other published reports of the sample entities. The sample consists of those 
members of the Hungarian Association of Pharmaceutical Manufacturers1 
which are engaged in R&D and Innovation. Since according to the Hungar-
ian Act of Accounting2 entities must report the expenses related to research 
and development in the narrative section of the financial statements, these 
sections of the most recent statements were examined and out of the 35 
members 10 firms were included in the sample as they disclosed R&D-related 
information for the year 2017. The sales revenues of the sample firms range 
between 3-1,300 million € which means that they all count as large entities in 
the Hungarian business environment. Out of the ten entities nine are private 
limited companies, and one is a public limited corporation. All of them com-
pose the Hungarian form of the so called full annual financial statements (with 
no exemptions regarding content), which were collected and analysed for the 
purpose of this research. 
In Hungarian regulations, the Business Report must be prepared and at-
tached to the financial statements but the law does not require entities to 
make it available online except for public companies. As a consequence, these 
were not downloadable in case of nine of the sample companies but was avail-
able for the single public entity. Based on the law3, as a public-interest en-
tity, one of the corporations must prepare an additional Non-financial State-
ment as part of the Business Report in which the impact of their operations 
on environment and society are also disclosed. Besides financial statements, 
we also checked whether any of the sample companies publish other types of 
voluntary statements (CSR or Sustainability Statements, GRI4 reports, etc.) on 
their websites. The sole public limited company published a so-called annual 
statement, which included dedicated chapter for financial data, information 
for shareholders, corporate governance, research and development, social re-
sponsibility and human resource among others.  For the rest of the sample 
companies no such reports were found online for the financial year 2017. 
After collecting the available statements, we comprised a list of the items 
based on which the content analysis was carried out. We defined 34 R&D-re-
lated items (see Table 1), most of which were included in Ragini’s (2012) re-
search. Items 1-20. comprise the R&D group in Ragini’s research. To these, we 
added six other items based on what we found in the annual statements (21-
1  https://www.magyosz.org/hu
2  Hungarian Act of Accounting: ’2000. évi C. törvény’, paragraph  92. § (4)
3  Hungarian Act of Accounting: ’2000. évi C. törvény’, paragraph  95. § 
4  Global Reporting Initiative
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26.). Items 27-34. were present in Ragini’s group for Intellectual Property, and 
we decided to include them to have some information about those results of 
research and development which are protected by law and help to achieve 
competitive advantage on the market.  The rest of the list (35-45.) are those 
pieces of information collected from Ragini’s which give us an idea about the 
firms’ attitude towards sustainability.
Table 1. List of the searched items
1. R & D Facilities 16. Technical know-How 31. Patent Ranking
2. R & D Activities* 17. New Technologies 32. Intellectual Property 
Cycle
3. R & D Personnel 18. Details Regarding 
Funding of R&D*
33. Intellectual Property 
Activities
4. R & D Focus Areas 19. Information Technology 
Initiatives
34. Intellectual Property 
Management
5. R & D Centres/ Bases 20. Information Related to 
Software Cost
35. Corporate Ethics/Code of 
Conduct
6. R & D Structure 21. Capitalized R&D in the 
Balance Sheet*
36. Environmental Activities*




8. R & D Results/
Achievements




9. R & D Expenditure* 24. R&D Income 39. Environmental Initiatives
10. R & D Expenditure as % 
of Sales
25. R&D Risks 40. Environmental 
Commitments*
11. Growth Rate of R&D 
Expenditure




12. Reason for the Increase or 
Decrease  in Expenditure
27. No. of Patents 42. Environmental Matters*
13. Information on 
Accounting Treatment of 
R&D Expenditure*
28. No. of Patents (area-wise) 43. Environmental 
Expenditure*
14. In-process Research and 
Development
29. Value of Patents 44. Products/Technologies 
Contributing to 
Environment*
15. Technology and 
Innovation
30. Value of Acquired Patents 45. Corporate Social 
Responsibility
Note: marked items are compulsory to disclose if relevant.
Source: own construction based on Ragini (2012)
The entities are required to disclose some of the listed items based on our 
accounting regulation if these are relevant (14 marked items in Table 1). It is 
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important to state that an if an entity does not include these items can simply 
mean that the item is nor relevant (for example there are no capitalized devel-
opment costs in the balance sheet, so items 21-23 will not be disclosed). What 
we can say that if these items are in the financial statements, then this is not 
voluntary disclosure but a mandatory one. The other 31 which are not marked 
are voluntary to communicate. 
Our results are concordant with earlier research stating that the disclo-
sure practices of Hungarian companies are deeply determined by the account-
ing regulations, and voluntary disclosure is very limited. Table 2. presents the 
number of the items included in the annual statements by companies. 




1. 2. 3. 4. 5. 6. 7. 8. 9. 10.
R&D&I Mandatory 3 4 7 7 6 3 3 3 2 1
Voluntary 1 0 0 15 3 1 0 0 0 1
Total 4 4 7 22 9 4 3 3 2 2
Sustainability Mandatory 1 3 2 6 5 0 3 1 0 0
Voluntary 0 0 0 4 0 0 0 0 0 0
Total 1 3 2 10 5 0 3 1 0 0
Source: own construction
Overall, the ten companies present on average 3.9 mandatory R&D&I 
elements and 2.1 voluntary items. On sustainability, the average number of 
reported mandatory items is 2.1, and the average of voluntary disclosed ele-
ments, is 0.4. However, it is obvious from the results that there is one outstand-
ing company which is not surprisingly the public company with the available 
business report and the non-financial statement integrated into the above 
mentioned annual report. If we remove this one company from the sample, the 
averages drop significantly – around zero – in the voluntary sections. Except 
for the mandatory items where it is 3.6 and 1.7. 
Publicly listed companies usually disclose more information on a volun-
tary basis, which is true for our sample as well. Since these companies tend to 
put more emphasis on transparency and communication with the stakehold-
ers, the voluntary items appear a lot more frequently. But as in Hungary the 
number of publicly listed companies at present is around 40, this is a very small 
minority from all operating entities. As a consequence of this, the most fre-
quently appearing items in the sample statements were among the compul-
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sory ones: R&D activities, R&D expenditure, Details regarding the funding of R&D, 
Environmental matters were reported by at least six entities. There were many 
items from the list that were not found in any of the statements, for example 
those related to Intellectual Property (32-34.).
Another important finding is that there were no examples in the financial 
statements for the companies to link the areas of R&D&I with sustainability. 
This does not mean that their strategies or policies lack the sustainability con-
siderations when it comes to research or innovation, but they certainly do not 
find it important to inform the stakeholders about such initiatives. 
4. CONCLUSION
The aim of this research was to explore the corporate reporting culture of 
Hungarian pharmaceutical firms and examine how they communicate about 
sustainability and R&D&I with the stakeholders. We applied a methodology 
that aims to find information related to the chosen topics in the mandatory 
and voluntary annual statements of firms. The main contribution of this phase 
to our planned research is that we were able to frame the list of 45 items by tak-
ing elements from earlier research and supplementing the list based on our ex-
periences. We applied manual content analysis based on a list and checked the 
reports of ten companies which are engaged in R&D. The results show that the 
reporting practices of the sample firms are determined by the requirements of 
the Hungarian Accounting Act. Voluntary reporting and voluntary disclosure 
were found only in case of the sole public entity in the sample, which present-
ed the highest scores. Another important finding is that the two areas of our 
interest were not interlinked in the statements, so companies did not report on 
the sustainability aspects of their research practices. Of course, sample size is a 
significant limitation of the research which also impedes comparison with the 
results of different studies at this point. In the future, additional results could 
be obtained by enlarging the sample which would make it possible to find var-
iables (e.g. profitability, firm size, ownership structure) that might explain the 
differences in disclosure scores. Another way of continuing the research could 
be the application other methods: qualitative research could definitely be use-
ful for discovering the motivations and barriers behind the reporting culture. 
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